Dermata Therapeutics Stock Price Prediction
DRMA Stock | USD 1.15 0.01 0.86% |
Oversold Vs Overbought
45
Oversold | Overbought |
EPS Estimate Next Quarter (1.36) | EPS Estimate Current Year (15.24) | EPS Estimate Next Year (3.87) | Wall Street Target Price 6 | EPS Estimate Current Quarter (2.64) |
Using Dermata Therapeutics hype-based prediction, you can estimate the value of Dermata Therapeutics from the perspective of Dermata Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Dermata Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Dermata because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Dermata Therapeutics after-hype prediction price | USD 1.16 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Dermata |
Dermata Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Dermata Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Dermata Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Dermata Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
Expected price to next headline |
Dermata Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Dermata Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Dermata Therapeutics' historical news coverage. Dermata Therapeutics' after-hype downside and upside margins for the prediction period are 0.06 and 9.60, respectively. We have considered Dermata Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Dermata Therapeutics is somewhat reliable at this time. Analysis and calculation of next after-hype price of Dermata Therapeutics is based on 3 months time horizon.
Dermata Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Dermata Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dermata Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Dermata Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.29 | 8.48 | 0.01 | 0.07 | 3 Events / Month | 4 Events / Month | In about 3 days |
Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.15 | 1.16 | 0.87 |
|
Dermata Therapeutics Hype Timeline
Dermata Therapeutics is currently traded for 1.15. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of 0.07. Dermata is expected to increase in value after the next headline, with the price projected to jump to 1.16 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 0.87%, whereas the daily expected return is currently at -0.29%. The volatility of related hype on Dermata Therapeutics is about 3713.87%, with the expected price after the next announcement by competition of 1.22. Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next expected press release will be in about 3 days. Check out Dermata Therapeutics Basic Forecasting Models to cross-verify your projections.Dermata Therapeutics Related Hype Analysis
Having access to credible news sources related to Dermata Therapeutics' direct competition is more important than ever and may enhance your ability to predict Dermata Therapeutics' future price movements. Getting to know how Dermata Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Dermata Therapeutics may potentially react to the hype associated with one of its peers.
HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
ZVSA | ZyVersa Therapeutics | (0.01) | 5 per month | 0.00 | (0.14) | 9.17 | (10.36) | 78.93 | |
SONN | Sonnet Biotherapeutics Holdings | 1.15 | 7 per month | 0.00 | (0.13) | 12.31 | (9.79) | 37.58 | |
ZURA | Zura Bio Limited | 0.03 | 9 per month | 0.00 | (0.05) | 7.95 | (7.94) | 30.69 | |
PHIO | Phio Pharmaceuticals Corp | 0.18 | 6 per month | 0.00 | (0.05) | 11.78 | (10.38) | 36.22 | |
RNAZ | Transcode Therapeutics | 0.04 | 2 per month | 6.52 | 0.07 | 22.00 | (11.43) | 68.80 | |
QNRX | Quoin Pharmaceuticals Ltd | (0.02) | 9 per month | 6.73 | 0.05 | 17.65 | (9.68) | 74.46 |
Dermata Therapeutics Additional Predictive Modules
Most predictive techniques to examine Dermata price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Dermata using various technical indicators. When you analyze Dermata charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
About Dermata Therapeutics Predictive Indicators
The successful prediction of Dermata Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Dermata Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Dermata Therapeutics based on analysis of Dermata Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Dermata Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Dermata Therapeutics's related companies.
Story Coverage note for Dermata Therapeutics
The number of cover stories for Dermata Therapeutics depends on current market conditions and Dermata Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Dermata Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Dermata Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Dermata Therapeutics Short Properties
Dermata Therapeutics' future price predictability will typically decrease when Dermata Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Dermata Therapeutics often depends not only on the future outlook of the potential Dermata Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Dermata Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 195 K | |
Cash And Short Term Investments | 7.4 M |
Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |